TAO Synergies (TAOX) Cash from Financing Activities (2020 - 2026)
TAO Synergies' (TAOX) quarterly Cash from Financing Activities came in at -$402371.0 in Q2 2026, down 108.41% on a YoY basis from $4.8 million in Q2 2025, and down 138.08% quarter-over-quarter from -$169006.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Cash from Financing Activities for 7 consecutive years, with -$402371.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 108.41% year-over-year to -$402371.0; the trailing twelve-month figure through Jun 2026 stood at $18.6 million (up 488.24% YoY), and the FY2025 full-year result was $23.1 million, up 551.67% from the prior year.
- Cash from Financing Activities eased to -$402371.0 in Q2 2026 per TAOX's latest filing, from -$169006.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $17.8 million in Q4 2025 and bottomed at -$822362.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $3.3 million across 5 years, with a median of $49.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 1571849.02% in 2024, then jumped 2323.73% in 2025.
- Over 5 years, Cash from Financing Activities stood at $13.9 million in 2022, then plunged by 100.0% to -$51.0 in 2023, then tumbled by 1571849.02% to -$801694.0 in 2024, then surged by 2323.73% to $17.8 million in 2025, then sank by 102.26% to -$402371.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$402371.0, -$169006.0, and $17.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -181.51 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -402,371.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -402,371.00 |
| Mar 31, 2026 | -169,006.00 |
| Dec 31, 2025 | 17.83 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 4.79 Mn |
| Mar 31, 2025 | -822,362.00 |
| Dec 31, 2024 | -801,694.00 |
| Dec 31, 2023 | -51.00 |
| Sep 30, 2023 | 49.00 |
| Dec 31, 2022 | 13.93 Mn |
| Mar 31, 2022 | 553,150.00 |
| Dec 31, 2021 | 4.97 Mn |
| Sep 30, 2021 | 672,795.00 |
| Jun 30, 2021 | 18.85 Mn |
| Mar 31, 2021 | 12.64 Mn |
| Dec 31, 2020 | -20.00 Mn |
| Mar 31, 2020 | 16.52 Mn |